Table 1.
Sequence and functional information for antigens identified in this study.
Figure 1.
Immunoreactivity of the PTCL, NOS-associated antigens with sera from patients with PTCL, NOS (n = 9), T-NHL (n = 15), B-NHL (n = 32) or healthy controls (n = 17).
Table 2.
Reactivity of antibodies present in the sera of lymphoma patients and normal control samples with the PTCL, NOS antigens.
Figure 2.
RT-PCR analysis of mRNA expression levels of genes encoding PTCL, NOS-associated antigens in cancer cell lines.
−, no reverse transcriptase negative control; +, positive control testis cDNA. TBP was included as a positive control for the quality of the cDNA.
Figure 3.
Quantitative real time PCR analysis of genes encoding PTCL, NOS-associated antigens in cancer cell lines.
Black bars represent T-cell lines, pale grey are Classical Hodgkin Lyphoma (CHL), white are myeloma and dark grey are B-NHL. Expression was normalised to fractionated normal CD19+ B cells for B-cell derived cell lines or fractionated normal CD3+ T cells for T-cell derived cell lines.
Figure 4.
RT-PCR analysis of PTCL, NOS SEREX antigens in fractionated peripheral blood cells.
1, resting CD4+T cells; 2, activated CD4+ T cells; 3, resting CD8+ T cells; 4, activated CD8+ T cells; 5, resting CD19+ B cells; 6, activated CD19+ B cells; 7, resting CD14+ monocytes; 8, activated monocytes; 9, mononuclear B and T cells; 10, positive control placenta tissue cDNA; 11, no reverse transcriptase negative control; 12, positive control Thiel cDNA.
Figure 5.
Western blot analysis of antibodies to PTCL, NOS SEREX antigens against selected whole cell RIPA extracts.
T-ALL, T cell acute lymphoblastic leukaemia; ALCL, ALK+; CTCL, cutaneous T cell lymphoma; FL, follicular lymphoma; GCB, germinal centre-derived diffuse large B cell lymphoma; ABC, activated B cell-derived diffuse large B cell lymphoma; BL, Burkitt lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin lymphoma; CML, chronic myelogenous leukaemia.